Application No.: 10/597,473

Attorney Docket No.: PR60714USw

## **Amendments to the Claims:**

Please amend the claims as follows:

1-2. (Cancelled)

- 3. (Currently amended) A compound as claimed in claim 15[[1]], wherein n is 1 or 2.
- 4. (Currently amended) A compound as claimed in claim  $\underline{15}[[1]]$ , wherein R2 is aryl, optionally substituted by one or two groups selected from the group consisting of halogen and  $C_{1.4}$ alkoxy.
- 5. (Currently amended) A compound as claimed in claim 15[[1]], wherein n is 0 and R1 and R2, together with the nitrogen atom to which they are joined, form a 6-membered monocyclic heterocyclic ring or a 10-membered bicyclic heterocyclic ring wherein at least the ring which each contains the nitrogen atom to which R1 and R2 are joined is non-aromatic, wherein the 6-membered monocyclic heterocyclic ring or 10-membered bicyclic heterocyclic ring are both optionally substituted by one or two groups selected from oxo, C<sub>1-4</sub>alkyl, phenyl and C<sub>1-4</sub>alkoxycarbonyl.
- 6-7. (Cancelled)
- 8. (Currently amended) A compound as claimed in claim 15[[1]], wherein X is a group:

wherein one of  $Y_1$  and  $Y_2$  is hydrogen, and the other is hydrogen, halogen or a group NR5R6 wherein R5 and R6 are independently hydrogen,  $C_{1-6}$ alkyl or  $C_{2-6}$ alkenyl.

- 9. (Currently amended) A compound selected from the group consisting of:
- 4-(2-amino-4-pyrimidinyl)-N-(3-methoxybenzyl)benzamide;
- N-(3-methoxybenzyl)-4-(4-pyrimidinyl)benzamide;
- 4-[6-(allylamino)-4-pyrimidinyl]-N-(3-methoxybenzyl)benzamide;
- 4-[6-amino-4-pyrimidinyl]-N-(3-methoxybenzyl)benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-{[3-(methyloxy)phenyl]methyl}benzamide;

Application No.: 10/597,473

Attorney Docket No.: PR60714USw

4-(2-{[4-(methyloxy)phenyl]amino}-4-pyrimidinyl)-N-{[3-

(methyloxy)phenyl]methyl}benzamide;

- 4-(2-amino-4-pyrimidinyl)-N-[(2-chlorophenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(4-chlorophenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(2-fluorophenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-{[2-(methyloxy)phenyl]methyl}benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(2-methylphenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-{[4-(methyloxy)phenyl]methyl}benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-(2,3-dihydro-1H-inden-1-yl)benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-{[3-(trifluoromethyl)phenyl]methyl}benzamide;
- 1,1-dimethylethyl({3-[({[4-(2-amino-4-

pyrimidinyl)phenyl]carbonyl}amino)methyl]phenyl}methyl)carbamate;

- 4-(2-amino-4-pyrimidinyl)-N-[(3-bromophenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(3-chlorophenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(3-fluorophenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-(phenylmethyl)benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-{(1\$)-1-[4-(methyloxy)phenyl]ethyl}benzamide:
- 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-phenylpropyl]benzamide;
- 6-(2-amino-4-pyrimidinyl)-2-(phenylmethyl)-1(2H)-isoquinolinone;
- 4-(2-amino-4-pyrimidinyl)-N-[(3-hydroxyphenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-({3-[(difluoromethyl)oxy]phenyl}methyl)benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-(1-methyl-1-phenylethyl)benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(3,5-dichlorophenyl)methyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-(4-biphenylylmethyl)benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylethyl]benzamide;
- 1,1-dimethylethyl{3-[1-({[4-(2-amino-4-

pyrimidinyl)phenyl]carbonyl}amino)ethyl]phenyl}carbamate;

- 4-(2-amino-4-pyrimidinyl)-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-{(1R)-1-[3-(methyloxy)phenyl]ethyl}benzamide;
- 4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylpropyl]benzamide; and salts thereof.

Application No.: 10/597,473

Attorney Docket No.: PR60714USw

10 – 13. (Cancelled)

- 14. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim <u>15[[1]]</u> and one or more of pharmaceutically acceptable carriers, diluents and excipients.
- 15. (New) A compound of Formula (la) or a salt thereof:

$$R1$$
(Ia)

## wherein:

- R1 is hydrogen;
- n is 1, 2, 3 or 4;
- R2 is aryl, optionally substituted by one or two groups selected from the group consisting of halogen, hydroxy, cyano, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, aryl, aryloxy, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkylsulfonyl, –R<sub>3</sub>R<sub>4</sub>NSO<sub>2</sub> (wherein R<sub>3</sub> and R<sub>4</sub> are independently hydrogen or C<sub>1-4</sub>alkyl), (CH<sub>2</sub>)<sub>0-3</sub>NHCOOC<sub>1-4</sub>alkyl, and a 5- or 6-membered heteroaryl group;
- or n is 0 and R1 and R2, together with the nitrogen atom to which they are joined, form a 5- or 6-membered monocyclic heterocyclic ring or a 9- or 10-membered bicyclic heterocyclic ring wherein at least the ring which contains the nitrogen atom to which R1 and R2 are joined is non-aromatic, and wherein the 5- or 6-membered monocyclic heterocyclic ring or the 9- or 10-membered bicyclic heterocyclic ring is optionally substituted by one or two groups selected from the group consisting of halogen, hydroxy, cyano, oxo, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkoxy, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, aryl, aryloxy and C<sub>1-4</sub>alkoxycarbonyl; and
- X is a group

Application No.: 10/597,473 Attorney Docket No.: PR60714USw

wherein

G is N; and

Y<sub>1</sub> and Y<sub>2</sub> are independently hydrogen, halogen and a group NR5R6 (wherein R5 and R6 are independently hydrogen, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, or